A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities

Journal of Evaluation in Clinical Practice

Volumn 17, Issue 2, 2011, Pages 288-297

  Zimovetz, Evelina A ^a   Wilson, Koo ^b   Samuel, Miny ^a   Beard, Stephen M ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Cost effectiveness analysis; Literature review; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPRATROPIUM BROMIDE; NICOTINE PATCH; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; VARENICLINE;

CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEART FAILURE; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SECONDARY PREVENTION; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE;

BENZAZEPINES; COST-BENEFIT ANALYSIS; HUMANS; MORBIDITY; NICOTINIC AGONISTS; QUINOXALINES; SMOKING;

EID: 79952634347     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2010.01439.x     Document Type: Review

References (48)

1. Cahill, K., Stead, L. F. & Lancaster, T. (2008) Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews, (3), CD006103. DOI: 10.1002/14651858.CD006103.pub3.
2. Fiore, M. C., Croyle, R. T., Curry, S. J., et al. (2004) Preventing 3 million deaths and helping 5 million smokers quit: a national action plan for tobacco cessation. American Journal of Public Health, 94 (2), 205-210. (Pubitemid 38176311)
3. World Health Report (2008) WHO report on the global tobacco epidemic. Available at: http://whqlibdoc.who.int/publications/2008/9789241596282-eng.pdf (last accessed 15 October 2009).
4. World Health Report (2007) The European tobacco control report 2007. Available at: http://www.euro.who.int/document/e89842.pdf (last accessed 29 October 2009).
5. Ezzati, M. & Lopez, A. D. (2004) Regional, disease specific patterns of smoking-attributable mortality in 2000. Tobacco Control, 13 (4), 388-395. (Pubitemid 39635926)
6. Ruff, L. K., Volmer, T., Nowak, D. & Meyer, A. (2000) The economic impact of smoking in Germany. European Respiratory Journal, 16 (3), 385-390.
7. Leal, J., Luengo-Fernández, R., Gray, A., Petersen, S. & Rayner, M. (2006) Economic burden of cardiovascular diseases in the enlarged European Union. European Heart Journal, 27 (13), 1610-1619. (Pubitemid 43954923)
8. Stead, L. F. & Lancaster, T. (2007) Interventions to reduce harm from continued tobacco use. Cochrane Database of Systematic Reviews, (3), CD005231.
9. Drummond, M. F., Sculpher, M. J., Torrance, G. W., O'Brien, B. J. & Stoddart, G. L. (1997) Methods for the Economics of Health Care Programmes, 2nd edn. New York: Oxford University Press.
10. Igarashi, A., Takuma, H., Fukuda, T. & Tsutani, K. (2009) Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics, 27 (3), 247-261.
11. Annemans, L., Nackaerts, K., Bartsch, P., Prignot, J. & Marbaix, S. (2009) Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clinical Drug Investigation, 29 (10), 655-665.
12. Bolin, K., Wilson, K., Benhaddi, H., Nigris, E. D., Marbaix, S., Mork, A. C. & Aubin, H. J. (2009) Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation - results from four European countries. European Journal of Public Health, 19 (6), 650-654. Epub 2009 Jun 2.
13. Bolin, K., Mork, A. C., Willers, S. & Lindgren, B. (2008) Varenicline as compared to bupropion in smoking-cessation therapy - costutility results for Sweden 2003. Respiratory Medicine, 102 (5), 699-710.
14. Howard, P., Knight, C., Boler, A. & Baker, C. (2008) Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US Adult smokers. PharmacoEconomics, 26 (6), 497-511.
15. Hoogendoorn, M., Welsing, P. & Rutten-van Mölken, M. P. (2008) Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Current Medical Research and Opinion, 24 (1), 51-61.
16. Heitjan, D. F., Asch, D. A., Ray, R., Rukstalis, M., Patterson, F. & Lerman, C. (2008) Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics Journal, 8 (6), 391-399.
17. Halpern, M. T., Dirani, R. & Schmier, J. K. (2007) The cost effectiveness of varenicline for smoking cessation. Managed Care Interface, 20 (10), 18-25.
18. Jackson, K. C., Nahoopii, R., Said, Q., Dirani, R. & Brixner, D. (2007) An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. Journal of Occupational and Environmental Medicine, 49 (4), 453-460. (Pubitemid 46624363)
19. Linden, K., Jormanainen, V., Linna, M., Sintonen, H., Wilson, K. & Kotomäki, T. (2010) Cost-effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Current Medical Research and Opinions, 26 (3), 549-560.
20. Linden, K., Kotomäki, T. & Wilson, K. Cost-effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in Finland. Poster presented at Society for Research on Nicotine and Tobacco, 10th Annual Conference; Rome, Italy. 23-26 September 2008.
21. Skoupá, J., Doležal, T., Hájek, P. & Kovář, P. (2008) Long-term cost-effectiveness analysis of varenicline versus nicotine replacement therapy, bupropion and unaided cessation for smoking cessation in the Czech Republic. Poster presented at the Society for Research on Nicotine and Tobacco, 10th Annual Conference; Rome, Italy. 23-26 September 2008.
22. De Bobadilla, J. F., Brosa, M., Wilson, K. & Maestre, C. S. (2007) Cost-effectiveness analysis of Champix® (varenicline) in smoking cessation treatment in Spain. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research, 10th Annual European Congress; Dublin, Ireland. 20 October 2007.
23. Poulsen, P. B., Dollerup, J. & Keiding, H. (2008) The cost-effectiveness of varenicline in smoking cessation in Denmark. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research, 11th Annual European Congress; Athens, Greece. 9 November 2008.
24. Brown, A., Webb, K., Kim, H. & Liew, D. (2008) Cost-effectiveness of smoking cessation in Australia with varenicline, a novel pharmacotherapy. Presentation made at the International Society for Pharmacoeconomics and Outcomes Research, 3rd Asia-Pacific Conference; Seoul, South Korea. 7 September 2008.
25. Viswanathan, S., Neville, W., Patel, E., Raparla, S. & McGhan, W. F. (2008) A cost-effectiveness model for smoking cessation therapy using varenicline. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research, 13th Annual International Meeting; Toronto, Ontario, Canada. 3 May 2008.
26. Bae, J. Y., Joe, K. H., Song, H. J., Kim, D. J. & Myung, S. (2008) A long-term cost-effectiveness analysis model for smoking cessation in Korea. Presented at the International Society for Pharmacoeconomics and Outcomes Research, 13th Annual International Meeting; Toronto, Ontario, Canada. May 2008.
27. Rasch, A., Lenz, C. & Greiner, W. (2007) Health economic model of smoking cessation treatment with varenicline in Germany. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research, 10th Annual European Congress; Dublin, Ireland. 20 October 2007.
28. Narváez, J., Alvis, N., Hoz, D. L., Orozco, J. & Porras, A. (2009) An economic evaluation of a pharmacological intervention using varenicline as therapy for smoking cessation. Abstract presented at the International Society for Pharmacoeconomics and Outcomes Research, 14th Annual International Meeting; Orlando, Florida, United States. 16 May 2009.
29. Bhatti, T.,Makino, K., Guarnieri, C., Gordois, A., Cotter, T., Perez, D., Bishop, J. & Glass, P. (2008) Cost-effectiveness analysis of smoking cessation pharmacotherapies in Australia. Abstract presented at the International Society for Pharmacoeconomics and Outcomes Research, 3rd Asia Pacific Conference; Seoul, South Korea. 7 September 2008.
30. Orme, M. E., Hogue, S. L., Kennedy, L. M., Paine, A. C. & Godfrey, C. (2001) Development of the health and economic consequences of smoking interactive model. Tobacco Control, 10, 55-61. (Pubitemid 33720569)
31. Drummond, M. F., Sculpher, M. J., Torrance, G. W., O'Brien, B. J. & Stoddart, G. L. (2005) Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. New York: Oxford University Press.
32. Keiding, H. (2009) Cost-effectiveness of varenicline for smoking cessation. Expert Review of Pharmacoeconomics and Outcomes Research, 9 (3), 215-221.
33. Vemer, P. & Rutten-van Molken, M. P. M. H. (2009) Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value in Health, 13 (2), 230-241.
34. Carlson, J. J., Veenstra, D. L. & Ramsey, S. D. (2008) Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs, 68 (8), 1105-1113.
35. Rutten-van Mölken, M. P., Oostenbrink, J. B., Miravitlles, M. & Monz, B. U. (2007) Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. European Journal of Health Economics, 8 (2), 123-135. (Pubitemid 46742896)
36. D'Souza, A. O., Smith, M. J., Miller, L. A. & Kavookjian, J. (2006) An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest, 129 (6), 1693-1708. (Pubitemid 43895002)
37. Oba, Y. (2007) Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clinic Proceedings, 82 (5), 575-582.
38. Ward, S., Lloyd, J. M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo,W. & Payne, N. (2007) Asystematic review and economic evaluation of statins for the prevention of coronary events (provisional abstract). Health Technology Assessment, 11, 1-178.
39. Levy, E. & Levy, P. (2002) Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies. Pharmaco-Economics, 20 (14), 963-977. (Pubitemid 35398695)
40. Dollerup, J., Poulsen, P. B., Randskov, H. J. & Petersen, K. M. (2008) Decision-making in healthcare using cost-effectiveness evidence: smoking cessation compared to treatment of smoking-related diseases. Poster presented at the Society for Research on Nicotine and Tobacco, 10th Annual Conference; Rome, Italy. 23-26 September 2008.
41. Fiore, M. C., Jaen, C. R., Baker, T. B., et al. (2008) Treating tobacco use and dependence: 2008 update. Available at: http://www.ncbi.nlm.nih.gov/ books/bv.fcgi?rid=hstat2.chapter.28163 (last accessed 15 October 2009).
42. Galanti, L. M. (2008) Tobacco smoking cessation management: integrating varenicline in current practice. Vascular Health and Risk Management, 4 (4), 837-845.
43. National Institute for Health and Clinical Excellence (2007) Varenicline for smoking cessation. Available at: http://www.nice.org.uk/nicemedia/pdf/ TA123Guidance.pdf (last accessed 15 October 2009).
44. Hind, D., Tappenden, P., Peters, J. & Kenjegalieva, K. (2007) Varenicline for smoking cessation: a single technology appraisal. ScHARR Report. Available at: http://www.ncchta.org/erg/reports/1643.pdf (last accessed 15 October 2009).
45. Menzin, J., Lines, L. M. &Marton, J. (2009) Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right? Expert Review of Pharmacoeconomics and Outcomes Research, 19 (3), 257-264.
46. Taylor, D. C., Chu, P., Rosen, V. M., Baker, C. L. & Thompson, D. (2009) Budgetary impact of varenicline in smoking cessation in the United Kingdom. Value in Health, 12 (1), 28-33.
47. Health and Social Care Information Centre (2005) Statistics on NHS stop smoking services in England, April 2004 to March 2005. Available at: http://www.dh.gov.uk/assetRoot/04/11/52/94/04115294.pdf (last accessed 4 November 2009).
48. Reda, A. A., Kaper, J., Fikrelter, H., Severens, J. L. & van-Schayck, C. P. (2009) Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database of Systematic Reviews, (2), Art. No.: CD004305. DOI: 10.1002/14651858.CD004305.pub3. John Wiley & Sons.